University of Michigan Medical School professor of Internal Medicine and Urology Dr. David C. Smith led a study on the drug cabozantinib and its effects on patients with prostate cancer that has spread to the bone.
Bone scans were used on the patients to measure the effect of the drug; 12% saw complete uptake and about 66% showed improvement in their bone scans.
Cabozantinib is designed to work on tumors that spread to the bone, which historically are difficult to treat. According to the study, a majority of patients saw a reduction in pain and some also reduced or eliminated narcotic painkillers after treatment.
For the full article, visit http://www.aalatimes.com/2012/12/09/drug-shows-promise-in-prostate-cancer-spread-to-bone/.
Bone scans were used on the patients to measure the effect of the drug; 12% saw complete uptake and about 66% showed improvement in their bone scans.
Cabozantinib is designed to work on tumors that spread to the bone, which historically are difficult to treat. According to the study, a majority of patients saw a reduction in pain and some also reduced or eliminated narcotic painkillers after treatment.
For the full article, visit http://www.aalatimes.com/2012/12/09/drug-shows-promise-in-prostate-cancer-spread-to-bone/.
No comments:
Post a Comment